Opko Health Inc. (OPK)
Opko Health Inc. is a healthcare company specializing in the development of innovative diagnostics and pharmaceuticals. Founded in 2007, the company focuses on personalized medicine, providing diagnostic tests and treatments in areas such as oncology, neurology, and infectious diseases. Its portfolio includes bio-pharmaceutical products, laboratory services, and consumer health products aimed at improving patient outcomes through targeted healthcare solutions.
Company News
Entera Bio reported better-than-expected Q2 2025 earnings with a GAAP EPS of $0.06, secured FDA regulatory concurrence for EB613's Phase 3 trial, and maintained a strong cash position of $18.8 million to support operations through mid-Q3 2026.
NextPlat's interim CEO David Phipps outlined strategic plans to improve healthcare and e-commerce divisions, focusing on operational efficiency, cost reduction, and exploring growth opportunities following the unexpected passing of former CEO Charles M. Fernandez.
OPKO Health, Inc. and Entera Bio Ltd. announced that OPKO's ModeX Therapeutics division has formed a Scientific Advisory Board with leaders in immunology and oncology drug development. Additionally, OPKO and Entera's first-in-class dual GLP-1/Glucagon tablet candidate for obesity and metabolic disorders has been selected for presentation at the ENDO 2025 Annual Meeting.
Opko Health, a significant shareholder in GeneDx Holdings Corp., has sold a portion of its stake in the company, selling 25,000 shares for a total transaction value of approximately $823,187.
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.